Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.57 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 1/20 | 0.55 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.55 |
| ▸ | TSHR | P16473 | 1/20 | 0.55 |
| ▸ | BLM | P54132 | 1/20 | 0.55 |
| ▸ | AGER | Q15109 | 1/20 | 0.55 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.53 |
| ▸ | NAPRT | Q6XQN6 | 2/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | GABRP | O00591 | 1/20 | 0.51 |
| ▸ | GABRD | O14764 | 1/20 | 0.51 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.51 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.51 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.51 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL17746080 | 0.98 | KDM4E (0.55) | KDM4ETDP1ALDH1A1L3MBTL1CYP3A4 | |
| Acetic Acid SCHEMBL16666942 | 0.96 | KDM4E (0.53) | KDM4ETDP1ALDH1A1L3MBTL1CYP3A4 | |
| SCHEMBL4407030 | 0.90 | KDM4E (0.47) | KDM4ETDP1ALDH1A1L3MBTL1CYP3A4 | |
| SCHEMBL9768749 | 0.86 | P2RX7 (0.44) | KDM4ETDP1ALDH1A1L3MBTL1CYP3A4 | |
| SCHEMBL258368 | 0.85 | KDM4E (0.53) | KDM4ETDP1ALDH1A1L3MBTL1CYP3A4 | |
| Imidazole SCHEMBL28450386 | 0.85 | KDM4E (0.42) | KDM4ETDP1ALDH1A1L3MBTL1CYP3A4 | |
| SCHEMBL7256602 | 0.85 | P2RX7 (0.43) | KDM4ETDP1ALDH1A1L3MBTL1CYP3A4 | |
| Hydrochloric Acid SCHEMBL5739430 | 0.84 | KDM4E (0.52) | KDM4ETDP1ALDH1A1L3MBTL1CYP3A4 | |
| SCHEMBL767027 | 0.83 | P2RX7 (0.46) | KDM4ETDP1ALDH1A1L3MBTL1CYP3A4 | |
| SCHEMBL353231 | 0.83 | KDM4E (0.55) | KDM4EALDH1A1MAPTSMN1; SMN2NAPRT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 224 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-221933883-U | Material feeding device for imazethapyr production | 潍坊先达化工有限公司 | 2024-11-01 | — | — | CN | claimed |
| EP-4448741-A2 | LIPASE FORMULATIONS AND METHODS THEREOF | First Wave Biopharma, Inc. (US) | 2024-10-23 | — | — | EP | claimed |
| CN-118525087-A | Lipase formulations and methods thereof | 第一浪潮生物制药有限公司 | 2024-08-20 | — | — | CN | claimed |
| WO-2024119044-A2 | ADRULIPASE COMPOSITIONS | First Wave BioPharma, Inc. (US) | 2024-06-06 | — | — | WO | claimed |
| CN-116437947-A | Non-pig formulations and methods thereof | 第一浪潮生物制药有限公司 | 2023-07-14 | — | — | CN | claimed |
| WO-2023114390-A2 | LIPASE FORMULATIONS AND METHODS THEREOF | First Wave BioPharma, Inc. (US) | 2023-06-22 | — | — | WO | claimed |
| EP-4167970-A1 | NON-PORCINE FORMULATIONS AND METHODS THEREOF | First Wave Biopharma, Inc. (US) | 2023-04-26 | — | — | EP | claimed |
| EP-3972569-A1 | NANOPARTICLES COMPRISING ENZALUTAMIDE | Helm AG (DE) | 2022-03-30 | — | — | EP | claimed |
| EP-2788323-B1 | NEW PROCESS AND INTERMEDIATES FOR THE SYNTHESIS OF VILDAGLIPTIN | CHEMELECTIVA SRL (IT) | 2017-01-11 | — | — | EP | claimed |
| EP-2788323-A1 | NEW PROCESS AND INTERMEDIATES FOR THE SYNTHESIS OF VILDAGLIPTIN | Chemelectiva Srl. (IT) | 2014-10-15 | — | — | EP | claimed |
| WO-2013083326-A1 | NEW PROCESS AND INTERMEDIATES FOR THE SYNTHESIS OF VILDAGLIPTIN | CHEMELECTIVA S.R.L. (IT) | 2013-06-13 | — | — | WO | claimed |
| US-7887840-B2 | Bioavailability of low- solubility drugs | BEND RESEARCH, INC. (US) | 2011-02-15 | — | — | US | claimed |
| EP-2275091-A1 | Pharmaceutical compositions comprising adsorbates of an amorphous drug | Pfizer Products Inc. (US) | 2011-01-19 | — | — | EP | claimed |
| US-20040147491-A1 | Prevent, maintenance of Dna damage; administering compound which forms nicotinamide-adenine dinucleotide | NIADYNE, INC. | 2004-07-29 | — | — | US | claimed |
| US-20010033848-A1 | Adjustment of cellular nicotinamide-adenine dinucleotide | NIADYNE, INC. | 2001-10-25 | — | — | US | claimed |
| EP-1143954-A2 | USE OF NICOTONIC ACID DERIVATIVES FOR THE TREATMENT OF DNA DAMAGE IN SKIN CELLS | University of Kentucky Research Foundation (US) | 2001-10-17 | — | — | EP | claimed |
| WO-2000032179-A2 | USE OF NICOTONIC ACID DERIVATIVES FOR THE TREATMENT OF DNA DAMAGE IN SKIN CELLS | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) | 2000-06-08 | — | — | WO | claimed |
| US-5259992-A | Cuprous iodide-pyridine derivative complex | REXHAM GRAPHICS INC. (US) | 1993-11-09 | — | — | US | claimed |
| EP-0117080-B1 | SKIN TREATMENT COMPOSITION | UNILEVER PLC (GB) | 1992-04-08 | — | — | EP | claimed |
| EP-4729052-A1 | SUSTAINED RELEASE DOSAGE FORM FOR LOW SOLUBILITY COMPOUND TETRAHYDROCANNABINOL AND METHODS FOR PREPARING OF THIS SUSTAINED RELEASE DOSAGE FORM | Emoviar PharmaCon GmbH (DE) | 2026-04-22 | — | — | EP | disclosed |
| EP-4729049-A1 | SUSTAINED RELEASE DOSAGE FORM FOR LOW SOLUBILITY COMPOUND AXITINIB AND METHODS FOR PREPARING OF THIS SUSTAINED RELEASE DOSAGE FORM | Emoviar PharmaCon GmbH (DE) | 2026-04-22 | — | — | EP | disclosed |
| US-12599610-B2 | Solid dosage formulations of an orexin receptor antagonist | MERCK SHARP & DOHME LLC (US) | 2026-04-14 | — | — | US | disclosed |
| CN-121779373-A | Synthesis method of imazethapyr | 辽宁优创植物保护有限公司 | 2026-04-03 | — | — | CN | disclosed |
| EP-3725778-B2 | FORMULATIONS OF ENZALUTAMIDE | MEDIVATION PROSTATE THERAPEUTICS LLC (US) | 2026-01-07 | — | — | EP | disclosed |
| CN-121220333-A | Weed prevention and control method for alfalfa-corn intercropping field | 青岛农业大学 | 2025-12-30 | — | — | CN | disclosed |
| US-12502357-B2 | Formulations of enzalutamide | ASTELLAS PHARMA INC. (JP) | 2025-12-23 | — | — | US | disclosed |
| US-12447128-B2 | Formulations of enzalutamide | ASTELLAS PHARMA INC. (JP) | 2025-10-21 | — | — | US | disclosed |
| EP-4616913-A2 | GCN2 INHIBITORS AND USES THEREOF | Merck Patent GmbH (DE) | 2025-09-17 | — | — | EP | disclosed |
| EP-3746075-B1 | GCN2 INHIBITORS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2025-09-03 | — | — | EP | disclosed |
| US-20250262166-A1 | NANOPARTICLES COMPRISING ENZALUTAMIDE | HELM AG (DE) | 2025-08-21 | — | — | US | disclosed |
| US-20250228840-A1 | METHODS OF TREATING SJÖGREN-LARSSEN SYNDROME | ALDEYRA THERAPEUTICS, INC. | 2025-07-17 | — | — | US | disclosed |
| US-20250221997-A1 | TYK2 INHIBITOR FORMULATIONS AND METHODS OF MAKING THE SAME | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2025-07-10 | — | — | US | disclosed |
| US-20250215002-A1 | SOLID FORMS OF TYK2 INHIBITORS AND METHODS OF USE | NIMBUS LAKSHMI, INC. | 2025-07-03 | — | — | US | disclosed |
| US-20250144098-A1 | FORMULATIONS OF PYRIMIDINE CYCLOHEXYL GLUCOCORTICOID RECEPTOR MODULATORS | CORCEPT THERAPEUTICS INCORPORATED | 2025-05-08 | — | — | US | disclosed |
| CN-119731146-A | (2, 4-Dichlorophenoxy) acetic acid analogues | 科迪华农业科技有限责任公司 | 2025-03-28 | — | — | CN | disclosed |
| CN-119241501-B | Hapten and complete antigen of imazethapyr as well as preparation methods and applications thereof | 中国农业科学院草原研究所 | 2025-03-25 | — | — | CN | disclosed |
| US-20250090465-A1 | Formulations of Enzalutamide | MEDIVATION LLC | 2025-03-20 | — | — | US | disclosed |
| US-20250049721-A1 | Formulations of Enzalutamide | ASTELLAS PHARMA INC (JP) | 2025-02-13 | — | — | US | disclosed |
| EP-4499645-A1 | SOLID FORMS OF TYK2 INHIBITORS AND METHODS OF USE | Takeda Pharmaceutical Company Limited (JP) | 2025-02-05 | — | — | EP | disclosed |
| EP-4499103-A1 | TYK2 INHIBITOR FORMULATIONS AND METHODS OF MAKING THE SAME | Takeda Pharmaceutical Company Limited (JP) | 2025-02-05 | — | — | EP | disclosed |
| CN-119241501-A | Hapten and complete antigen of imazethapyr as well as preparation methods and applications thereof | 中国农业科学院草原研究所 | 2025-01-03 | — | — | CN | disclosed |
| US-12178827-B2 | Nicotinyl riboside compounds and their uses | MITOPOWER LLC (US) | 2024-12-31 | — | — | US | disclosed |
| US-12144812-B2 | Formulations of pyrimidine cyclohexyl glucocorticoid receptor modulators | CORCEPT THERAPEUTICS INCORPORATED (US) | 2024-11-19 | — | — | US | disclosed |
| US-20240350642-A1 | SUSTAINED RELEASE DOSAGE FORMS FOR LOW SOLUBILITY COMPOUNDS AND METHODS FOR PREPARING OF THESE SUSTAINED RELEASE DOSAGE FORMS | EMOVIAR PHARMACON GMBH (DE) | 2024-10-24 | — | — | US | disclosed |
| EP-4447999-A1 | STABLE LIPASE FORMULATIONS AND METHODS THEREOF | First Wave Biopharma, Inc. (US) | 2024-10-23 | — | — | EP | disclosed |
| EP-4448741-A2 | LIPASE FORMULATIONS AND METHODS THEREOF | First Wave Biopharma, Inc. (US) | 2024-10-23 | — | — | EP | disclosed |
| EP-4450130-A2 | FORMULATIONS OF ENZALUTAMIDE | Medivation Prostate Therapeutics LLC (US) | 2024-10-23 | — | — | EP | disclosed |
| WO-2024213341-A1 | SUSTAINED RELEASE DOSAGE FORMS COMPRISING COMPLEXES OF LOW SOLUTIBILITY COMPOUNDS, AND METHODS FOR THEIR PREPARATION | EMOVIAR PHARMACON GMBH (DE) | 2024-10-17 | — | — | WO | disclosed |
| EP-4445898-A1 | SUSTAINED RELEASE DOSAGE FORMS COMPRISING COMPLEXES OF LOW SOLUTIBILITY COMPOUNDS, AND METHODS FOR THEIR PREPARATION | Emoviar PharmaCon GmbH (DE) | 2024-10-16 | — | — | EP | disclosed |
| EP-4445899-A1 | SUSTAINED RELEASE DOSAGE FORMS COMPRISING COMPLEXES OF LOW SOLUTIBILITY COMPOUNDS, AND METHODS FOR THEIR PREPARATION | Emoviar PharmaCon GmbH (DE) | 2024-10-16 | — | — | EP | disclosed |
| US-12064516-B2 | Pharmaceutical formulations and uses thereof | ALDEYRA THERAPEUTICS, INC. (US) | 2024-08-20 | — | — | US | disclosed |
| CN-118525087-A | Lipase formulations and methods thereof | 第一浪潮生物制药有限公司 | 2024-08-20 | — | — | CN | disclosed |
| US-20240261282-A1 | PHARMACEUTICAL COMPOSITIONS AND COMBINATIONS COMPRISING INHIBITORS OF THE ANDROGEN RECEPTOR AND USES THEREOF | ESSA PHARMA INC (CA) | 2024-08-08 | — | — | US | disclosed |
| US-20240261299-A1 | SOLID DOSAGE FORMULATIONS OF AN OREXIN RECEPTOR ANTAGONIST | MERCK SHARP & DOHME LLC (US) | 2024-08-08 | — | — | US | disclosed |
| WO-2023114383-A9 | STABLE LIPASE FORMULATIONS AND METHODS THEREOF | First Wave BioPharma, Inc. (US) | 2024-07-04 | — | — | WO | disclosed |
| US-20240207264-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING INHIBITORS OF THE ANDROGEN RECEPTOR AND USES THEREOF | ESSA PHARMA INC. (CA) | 2024-06-27 | — | — | US | disclosed |
| US-20240197661-A1 | ORAL DOSAGE FORMS OF METHYL HYDROGEN FUMARATE AND PRODRUGS THEREOF | HPS INVESTMENT PARTNERS, LLC, AS ADMINISTRATIVE AGENT | 2024-06-20 | — | — | US | disclosed |
| WO-2024119044-A2 | ADRULIPASE COMPOSITIONS | First Wave BioPharma, Inc. (US) | 2024-06-06 | — | — | WO | disclosed |
| CN-118063430-A | Method and equipment for purifying imazethapyr | 内蒙古新农基科技有限公司 | 2024-05-24 | — | — | CN | disclosed |
| CN-118044519-A | Molecules having pesticidal utility, and intermediates, compositions and methods related thereto | 科迪华农业科技有限责任公司 | 2024-05-17 | — | — | CN | disclosed |
| US-11980623-B2 | Solid dosage formulations of an orexin receptor antagonist | MERCK SHARP & DOHME LLC (US) | 2024-05-14 | — | — | US | disclosed |
| CN-118005640-A | GCN2 inhibitors and uses thereof | 默克专利股份有限公司 | 2024-05-10 | — | — | CN | disclosed |
| EP-4324527-A2 | FORMULATIONS OF ENZALUTAMIDE | Medivation Prostate Therapeutics LLC (US) | 2024-02-21 | — | — | EP | disclosed |
| US-20240050459-A1 | Nicotinyl Riboside Compounds and Their Uses | MITOPOWER LLC | 2024-02-15 | — | — | US | disclosed |
| US-11897866-B2 | Heteroaryl inhibitors of PAD4 | PADLOCK THERAPEUTICS, INC. (US) | 2024-02-13 | — | — | US | disclosed |
| CN-111918651-B | GCN2 inhibitors and uses thereof | 默克专利股份有限公司 | 2024-01-30 | — | — | CN | disclosed |
| US-20240024249-A1 | ORAL DOSAGE FORMS HAVING A HIGH LOADING OF A METHYL HYDROGEN FUMARATE PRODRUG | HPS INVESTMENT PARTNERS, LLC, AS ADMINISTRATIVE AGENT | 2024-01-25 | — | — | US | disclosed |
| US-11839689-B2 | Formulations of enzalutamide | ASTELLAS PHARMA INC. (JP) | 2023-12-12 | — | — | US | disclosed |
| US-11833167-B2 | Nicotinyl riboside compounds and their uses | MITOPOWER LLC (US) | 2023-12-05 | — | — | US | disclosed |
| CN-117122271-A | Wearable device for skin testing | 上海添音生物科技有限公司 | 2023-11-28 | — | — | CN | disclosed |
| CN-116887675-A | Herbicidal compositions comprising imidazolinone-based acetolactate synthase inhibitors and uses thereof | 安道麦阿甘有限公司 | 2023-10-13 | — | — | CN | disclosed |
| WO-2023192372-A1 | METHODS OF TREATING SJÖGREN-LARSSEN SYNDROME | ALDEYRA THERAPEUTICS, INC. (US) | 2023-10-05 | — | — | WO | disclosed |
| WO-2023183900-A1 | TYK2 INHIBITOR FORMULATIONS AND METHODS OF MAKING THE SAME | NIMBUS LAKSHMI, INC. (US) | 2023-09-28 | — | — | WO | disclosed |
| WO-2023183910-A1 | SOLID FORMS OF TYK2 INHIBITORS AND METHODS OF USE | NIMBUS LAKSHMI, INC. (US) | 2023-09-28 | — | — | WO | disclosed |
| US-20230255995-A1 | Nicotinyl Riboside Compounds and Their Uses | MITOPOWER LLC | 2023-08-17 | — | — | US | disclosed |
| CN-116516055-A | InDel marker primer pair for long mixed grain 2922 seed purity and identification method and application thereof | 山西农业大学谷子研究所(山西省农业科学院谷子研究所) | 2023-08-01 | — | — | CN | disclosed |
| CN-116437947-A | Non-pig formulations and methods thereof | 第一浪潮生物制药有限公司 | 2023-07-14 | — | — | CN | disclosed |
| US-20230210782-A1 | NON-PORCINE FORMULATIONS AND METHODS THEREOF | First Wave BioPharma, Inc. | 2023-07-06 | — | — | US | disclosed |
| US-20230210778-A1 | Formulations of Enzalutamide | ASTELLAS PHARMA INC. (JP) | 2023-07-06 | — | — | US | disclosed |
| WO-2023114383-A1 | STABLE LIPASE FORMULATIONS AND METHODS THEREOF | First Wave BioPharma, Inc. (US) | 2023-06-22 | — | — | WO | disclosed |
| WO-2023114390-A2 | LIPASE FORMULATIONS AND METHODS THEREOF | First Wave BioPharma, Inc. (US) | 2023-06-22 | — | — | WO | disclosed |
| US-20230190888-A1 | STABLE LIPASE FORMULATIONS AND METHODS THEREOF | First Wave BioPharma, Inc. | 2023-06-22 | — | — | US | disclosed |
| US-20230193228-A1 | LIPASE FORMULATIONS AND METHODS THEREOF | First Wave BioPharma, Inc. | 2023-06-22 | — | — | US | disclosed |
| EP-2865369-B1 | Solid dispersions of isoxazoline compounds | SUMITOMO CHEMICAL CO (JP) | 2023-05-24 | — | — | EP | disclosed |
| EP-4167970-A1 | NON-PORCINE FORMULATIONS AND METHODS THEREOF | First Wave Biopharma, Inc. (US) | 2023-04-26 | — | — | EP | disclosed |
| EP-4169908-A1 | FORMULATIONS OF ENZALUTAMIDE | Medivation Prostate Therapeutics LLC (US) | 2023-04-26 | — | — | EP | disclosed |
| US-11633414-B2 | Nicotinoyl riboside compositions and methods of use | CORNELL UNIVERSITY (US) | 2023-04-25 | — | — | US | disclosed |
| US-20230122911-A1 | FORMULATIONS OF ENZALUTAMIDE | MEDIVATION PROSTATE THERAPEUTICS LLC | 2023-04-20 | — | — | US | disclosed |
| EP-4149470-A1 | PHARMACEUTICAL FORMULATIONS AND USES THEREOF | Aldeyra Therapeutics, Inc. (US) | 2023-03-22 | — | — | EP | disclosed |
| US-20220340577-A1 | GCN2 INHIBITORS AND USES THEREOF | VERTEX PHARMACEUTICALS INCORPORATED | 2022-10-27 | — | — | US | disclosed |
| US-20220340577-A1 | GCN2 INHIBITORS AND USES THEREOF | VERTEX PHARMACEUTICALS INCORPORATED | 2022-10-27 | — | — | US | disclosed |
| US-20220249388-A1 | NANOPARTICLES COMPRISING ENZALUTAMIDE | HELM AG (DE) | 2022-08-11 | — | — | US | disclosed |
| US-20220241208-A1 | PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF HBV | ASSEMBLY BIOSCIENCES, INC. | 2022-08-04 | — | — | US | disclosed |
| EP-3986420-A1 | NICOTINYL RIBOSIDE COMPOUNDS AND THEIR USES | Mitopower LLC (US) | 2022-04-27 | — | — | EP | disclosed |
| CN-111593031-B | Rice ALS mutant gene, plant transgenic screening vector pCALSm3 containing gene and application thereof | 海南波莲水稻基因科技有限公司 | 2022-04-08 | — | — | CN | disclosed |
| US-20220105093-A1 | PHARMACEUTICAL COMPOSITIONS AND COMBINATIONS COMPRISING INHIBITORS OF THE ANDROGEN RECEPTOR AND USES THEREOF | ESSA PHARMACEUTICALS CORP. (CA) | 2022-04-07 | — | — | US | disclosed |
| EP-3975996-A1 | PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF HBV | Assembly Biosciences, Inc. (US) | 2022-04-06 | — | — | EP | disclosed |
| EP-3972569-A1 | NANOPARTICLES COMPRISING ENZALUTAMIDE | Helm AG (DE) | 2022-03-30 | — | — | EP | disclosed |
| US-11286274-B2 | Nicotinamide riboside derivatives and their uses | MITOPOWER LLC (US) | 2022-03-29 | — | — | US | disclosed |
| CN-111560396-B | Plant transgenic screening vector pCALSm1 and application thereof | 海南波莲水稻基因科技有限公司 | 2022-03-25 | — | — | CN | disclosed |
| EP-3971167-A1 | FORMULATIONS OF ENZALUTAMIDE | Medivation Prostate Therapeutics LLC (US) | 2022-03-23 | — | — | EP | disclosed |
| US-20220081418-A1 | HETEROARYL INHIBITORS OF PAD4 | PADLOCK THERAPEUTICS INC (US) | 2022-03-17 | — | — | US | disclosed |
| WO-2022054096-A1 | SOLID FORMS OF SUBSTITUTED POLYCYCLIC PYRIDONE COMPOUNDS AND PRODRUGS THEROF AND PROCESS OF PREPARATION THEREOF | CIPLA LIMITED (IN) | 2022-03-17 | — | — | WO | disclosed |
| WO-2022049075-A1 | AMORPHOUS SOLID DISPERSION OF DAROLUTAMIDE | BEND RESEARCH, INC. (US) | 2022-03-10 | — | — | WO | disclosed |
| US-11266614-B2 | Oral formulations of belinostat | ONXEO (FR) | 2022-03-08 | — | — | US | disclosed |
| US-20220062314-A1 | NICOTINYL RIBOSIDE COMPOUNDS AND THEIR USES | MitoPower, LLC (US) | 2022-03-03 | — | — | US | disclosed |
| US-20220062295-A1 | SOLID DOSAGE FORMULATIONS OF AN OREXIN RECEPTOR ANTAGONIST | MERCK SHARP & DOHME CORP. (US) | 2022-03-03 | — | — | US | disclosed |
| US-11198681-B2 | Heteroaryl inhibitors of PAD4 | PADLOCK THERAPEUTICS, INC. (US) | 2021-12-14 | — | — | US | disclosed |
| US-11198681-B2 | Heteroaryl inhibitors of PAD4 | PADLOCK THERAPEUTICS, INC. (US) | 2021-12-14 | — | — | US | disclosed |
| EP-3897666-A2 | NICOTINYL RIBOSIDE COMPOUNDS AND THEIR USES | Mitopower LLC (US) | 2021-10-27 | — | — | EP | disclosed |
| CN-109071497-B | PAD4 heteroaryl inhibitors | 帕德罗科治疗公司 | 2021-10-22 | — | — | CN | disclosed |
| US-20210188810-A1 | HETEROARYL INHIBITORS OF PAD4 | PADLOCK THERAPEUTICS INC (US) | 2021-06-24 | — | — | US | disclosed |
| US-20210188810-A1 | HETEROARYL INHIBITORS OF PAD4 | PADLOCK THERAPEUTICS INC (US) | 2021-06-24 | — | — | US | disclosed |
| WO-2021080330-A1 | NICOTINAMIDE COMPOUND AND HERBICIDAL COMPOSITION COMPRISING COMPOUND | 한국화학연구원 | 2021-04-29 | — | — | WO | disclosed |
| US-10988477-B2 | GCN2 inhibitors and uses thereof | MERCK PATENT GMBH (DE) | 2021-04-27 | — | — | US | disclosed |
| US-10988477-B2 | GCN2 inhibitors and uses thereof | MERCK PATENT GMBH (DE) | 2021-04-27 | — | — | US | disclosed |
| CN-107846888-B | Heterocyclic compounds as pesticides | 拜耳作物科学股份公司 | 2021-02-26 | — | — | CN | disclosed |
| WO-2020257283-A1 | NICOTINYL RIBOSIDE COMPOUNDS AND THEIR USES | MITOPOWER LLC (US) | 2020-12-24 | — | — | WO | disclosed |
| US-20200397807-A1 | NICOTINYL RIBOSIDE COMPOUNDS AND THEIR USES | MITOPOWER LLC | 2020-12-24 | — | — | US | disclosed |
| EP-3746075-A1 | GCN2 INHIBITORS AND USES THEREOF | Merck Patent GmbH (DE) | 2020-12-09 | — | — | EP | disclosed |
| CN-111918651-A | GCN2 inhibitors and uses thereof | 默克专利股份有限公司 | 2020-11-10 | — | — | CN | disclosed |
| US-20200347045-A1 | CRBN LIGANDS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2020-11-05 | — | — | US | disclosed |
| EP-3707138-A1 | ISOFURANONE COMPOUNDS USEFUL AS HPK1 INHIBITORS | Bristol-Myers Squibb Company (US) | 2020-09-16 | — | — | EP | disclosed |
| WO-2020131578-A2 | NICOTINYL RIBOSIDE COMPOUNDS AND THEIR USES | MITOPOWER LLC (US) | 2020-06-25 | — | — | WO | disclosed |
| CN-111094473-A | Aqueous dispersion and aqueous coating composition comprising the same | 陶氏环球技术有限责任公司 | 2020-05-01 | — | — | CN | disclosed |
| EP-3642214-A2 | NICOTINAMIDE RIBOSIDE DERIVATIVES AND THEIR USES | Ganapati, Gangadhara (US) | 2020-04-29 | — | — | EP | disclosed |
| WO-2019148132-A1 | GCN2 INHIBITORS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2019-08-01 | — | — | WO | disclosed |
| US-20190233425-A1 | GCN2 INHIBITORS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2019-08-01 | — | — | US | disclosed |
| US-20190233425-A1 | GCN2 INHIBITORS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2019-08-01 | — | — | US | disclosed |
| CN-105722392-B | Compositions of non-nucleoside reverse transcriptase inhibitors | 默沙东公司 | 2019-07-23 | — | — | CN | disclosed |
| EP-3419969-A1 | HETEROARYL INHIBITORS OF PAD4 | Padlock Therapeutics, Inc. (US) | 2019-01-02 | — | — | EP | disclosed |
| WO-2018236814-A2 | NICOTINAMIDE RIBOSIDE DERIVATIVES AND THEIR USES | GANAPATI GANGADHARA (US) | 2018-12-27 | — | — | WO | disclosed |
| CN-109078015-A | The solid dosage of orexin receptor antagonists | 默沙东公司 | 2018-12-25 | — | — | CN | disclosed |
| CN-109071497-A | PAD4 heteroaryl inhibitors | 帕德罗科治疗公司 | 2018-12-21 | — | — | CN | disclosed |
| US-20180362570-A1 | NICOTINAMIDE RIBOSIDE DERIVATIVES AND THEIR USES | MITOPOWER LLC | 2018-12-20 | — | — | US | disclosed |
| CN-108828114-A | A kind of method of solid phase microextraction-mass spectrometry on-line preconcentration detection Performance Liquid Chromatography Analysis for Nicotine in Tobacco class compound | 复旦大学 | 2018-11-16 | — | — | CN | disclosed |
| WO-2017147102-A1 | HETEROARYL INHIBITORS OF PAD4 | PADLOCK THERAPEUTICS, INC. (US) | 2017-08-31 | — | — | WO | disclosed |
| CN-103649053-B | Aminomethyl quinolone compounds | 霍夫曼-拉罗奇有限公司 | 2017-07-04 | — | — | CN | disclosed |
| CN-106614720-A | Thiamethoxam for controlling defoliators in forestry | 重庆安尚园农业科技发展有限公司 | 2017-05-10 | — | — | CN | disclosed |
| EP-2788323-B1 | NEW PROCESS AND INTERMEDIATES FOR THE SYNTHESIS OF VILDAGLIPTIN | CHEMELECTIVA SRL (IT) | 2017-01-11 | — | — | EP | disclosed |
| EP-3010885-A1 | INTERMEDIATES USEFUL FOR THE PREPARATION OF SAXAGLIPTIN | Chemelectiva Srl. (IT) | 2016-04-27 | — | — | EP | disclosed |
| US-20160107992-A1 | INTERMEDIATES USEFUL FOR THE PREPARATION OF SAXAGLIPTIN | CHEMELECTIVA S.R.L. (IT) | 2016-04-21 | — | — | US | disclosed |
| EP-2900223-A1 | NOVEL COMPOUNDS THAT ARE ERK INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2015-08-05 | — | — | EP | disclosed |
| WO-2014202668-A1 | INTERMEDIATES USEFUL FOR THE PREPARATION OF SAXAGLIPTIN | CHEMELECTIVA S.R.L. (IT) | 2014-12-24 | — | — | WO | disclosed |
| EP-2788323-A1 | NEW PROCESS AND INTERMEDIATES FOR THE SYNTHESIS OF VILDAGLIPTIN | Chemelectiva Srl. (IT) | 2014-10-15 | — | — | EP | disclosed |
| EP-2590943-B1 | PROCESS AND INTERMEDIATES FOR PREPARATION OF AN ACTIVE INGREDIENT | CHEMELECTIVA SRL (IT) | 2014-10-01 | — | — | EP | disclosed |
| WO-2013175395-A2 | IMPROVED PROCESS FOR PREPARATION OF SAXAGLIPTIN AND ITS SALTS | DR. REDDYS LABORATORIES LIMITED (IN) | 2013-11-28 | — | — | WO | disclosed |
| WO-2013083326-A1 | NEW PROCESS AND INTERMEDIATES FOR THE SYNTHESIS OF VILDAGLIPTIN | CHEMELECTIVA S.R.L. (IT) | 2013-06-13 | — | — | WO | disclosed |
| EP-2590943-A1 | PROCESS AND INTERMEDIATES FOR PREPARATION OF AN ACTIVE INGREDIENT | Chemelectiva Srl. (IT) | 2013-05-15 | — | — | EP | disclosed |
| US-20120308588-A1 | NEPRILYSIN INHIBITORS | THERAVANCE, INC. (US) | 2012-12-06 | — | — | US | disclosed |
| EP-2442791-A1 | DOSAGE FORMS OF APIXABAN | Pfizer Inc. (US) | 2012-04-25 | — | — | EP | disclosed |
| US-20120087978-A1 | DOSAGE FORMS OF APIXABAN | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-04-12 | — | — | US | disclosed |
| US-8147872-B2 | Pharmaceutical compositions of drugs and neutralized acidic polymers | Bend Reseach, Inc. (US) | 2012-04-03 | — | — | US | disclosed |
| EP-1653928-B1 | SPRAY DRYING PROCESSES FOR FORMING SOLID AMORPHOUS DISPERSIONS OF DRUGS AND POLYMERS | BEND RES INC (US) | 2012-03-07 | — | — | EP | disclosed |
| WO-2012004210-A1 | PROCESS AND INTERMEDIATES FOR PREPARATION OF AN ACTIVE INGREDIENT | CHEMELECTIVA SRL (IT) | 2012-01-12 | — | — | WO | disclosed |
| EP-1653927-B1 | PHARMACEUTICAL COMPOSITIONS OF ADSORBATES OF AMORPHOUS DRUGS AND LIPOPHILIC MICROPHASE-FORMING MATERIALS | BEND RES INC (US) | 2012-01-11 | — | — | EP | disclosed |
| US-20110311621-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS OF DELVERY | CHIASMA, INC. | 2011-12-22 | — | — | US | disclosed |
| US-20110277339-A1 | METHOD FOR MAKING HOMOGENEOUS SPRAY-DRIED SOLID AMORPHOUS DRUG DISPERSIONS UTILIZING MODIFIED SPRAY-DRYING APPARATUS | LONZA BEND INC. | 2011-11-17 | — | — | US | disclosed |
| US-8048452-B2 | Pharmaceutical compositions of cholesteryl ester transfer protein inhibitor | BEND RESEARCH, INC. (US) | 2011-11-01 | — | — | US | disclosed |
| US-8030359-B2 | Polymer formulations of CETP inhibitors | MERCK SHARP & DOHME CORP. (US) | 2011-10-04 | — | — | US | disclosed |
| US-8026286-B2 | Pharmaceutical compositions providing enhanced drug concentrations | BEND RESEARCH, INC. (US) | 2011-09-27 | — | — | US | disclosed |
| WO-2011116139-A2 | IMPROVED PHARMACEUTICAL COMPOSITIONS AND METHODS OF DELIVERY | CHIASMA INC. (US) | 2011-09-22 | — | — | WO | disclosed |
| WO-2011116115-A1 | ALISKIREN COMPOSITION COMPRISING A MEDIUM CHAIN FATTY ACID, THEIR PROCESS OF MANUFACTURING | NOVARTIS AG (CH) | 2011-09-22 | — | — | WO | disclosed |
| US-8003672-B2 | CB-1 receptor modulator formulations | MERCK SHARP & DOHME CORP. (US) | 2011-08-23 | — | — | US | disclosed |
| WO-2011060084-A1 | STABILIZED FORMULATIONS OF FATTY ACIDS | MyCell Holdings Limited (US) | 2011-05-19 | — | — | WO | disclosed |
| US-20110118351-A1 | Stabilized Formulations of Fatty Acids | MyCell Holdings Limited | 2011-05-19 | — | — | US | disclosed |
| US-20110111998-A1 | MODIFICATION OF PARTICULATE-STABILISED FLUID-FLUID INTERFACES | CONOPCO, INC. D/B/A UNILEVER | 2011-05-12 | — | — | US | disclosed |
| EP-2305217-A1 | Method for the preparation of pharmaceutical compositions comprising a solid amorphous dispersion of cholesteryl ester transfer protein inhibitors | Bend Research, Inc. (US) | 2011-04-06 | — | — | EP | disclosed |
| EP-1305007-B1 | PHARMACEUTICAL COMPOSITIONS OF CHOLESTERYL ESTER TRANSFER PROTEIN INHIBITORS | BEND RES INC (US) | 2011-03-30 | — | — | EP | disclosed |
| US-7897175-B2 | Cholesteryl ester transfer protein (CETP) such as torcetrapib; 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMG-CoA reductase); two drugs are separate from each other; improved chemical stability of the HMG-CoA reductase inhibitor | BEND RESEARCH, INC. (US) | 2011-03-01 | — | — | US | disclosed |
| EP-2283822-A2 | Spray drying processes for forming solid amorphous dispersions of drugs and polymers | BEND RESEARCH, INC. (US) | 2011-02-16 | — | — | EP | disclosed |
| US-7887840-B2 | Bioavailability of low- solubility drugs | BEND RESEARCH, INC. (US) | 2011-02-15 | — | — | US | disclosed |
| EP-2275091-A1 | Pharmaceutical compositions comprising adsorbates of an amorphous drug | Pfizer Products Inc. (US) | 2011-01-19 | — | — | EP | disclosed |
| US-20100273757-A1 | PYRAZINE DERIVATIVES USEFUL AS ADENOSINE RECEPTOR ANTAGONISTS | LABORATORIOS ALMIRALL, S.A. | 2010-10-28 | — | — | US | disclosed |
| US-20100234339-A1 | SILVER(I) COMPOUNDS AND THEIR USE IN PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT,PROPHYLAXIS AND PREVENTION OF INFECTIONS | CSE INCUBATION AB | 2010-09-16 | — | — | US | disclosed |
| US-7790728-B2 | Pyrazine derivatives useful as adenosine receptor antagonists | LABORATORIOS ALMIRALL, S.A. (ES) | 2010-09-07 | — | — | US | disclosed |
| EP-2167087-A1 | NEW SILVER(I) COMPOUNDS AND THEIR USE IN PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT, PROPHYLAXIS AND PREVENTION OF INFECTIONS | CSE Incubation AB (SE) | 2010-03-31 | — | — | EP | disclosed |
| US-7612070-B2 | Heterocyclic compounds as antiinflammatory agents and cyclooxygenase inhibitors | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2009-11-03 | — | — | US | disclosed |
| US-7612070-B2 | Heterocyclic compounds as antiinflammatory agents and cyclooxygenase inhibitors | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2009-11-03 | — | — | US | disclosed |
| WO-2008145759-A9 | NEW SILVER(I) COMPOUNDS AND THEIR USE IN PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT, PROPHYLAXIS AND PREVENTION OF INFECTIONS | CSE INCUBATION AB (SE) | 2009-02-26 | — | — | WO | disclosed |
| US-20090042891-A1 | Pyrazine Derivatives Useful as Adenosine Receptor Antagonists | LABORATORIOS ALMIRALL, S.A. (ES) | 2009-02-12 | — | — | US | disclosed |
| WO-2009010296-A2 | ANTIBODIES AGAINST 4-(METHYLNITROSAMINO)-1-(3-PYRIDYL)-1-BUTANONE AND METABOLITES THEREOF | CENTRE DE RECHERCHE PUBLIQUE SANTÉ (LU) | 2009-01-22 | — | — | WO | disclosed |
| EP-2016954-A1 | Antibodies against 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone and metabolites thereof | Muller, Claude P. (LU) | 2009-01-21 | — | — | EP | disclosed |
| WO-2008145759-A1 | NEW SILVER(I) COMPOUNDS AND THEIR USE IN PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT, PROPHYLAXIS AND PREVENTION OF INFECTIONS | CSE INCUBATION AB (SE) | 2008-12-04 | — | — | WO | disclosed |
| US-7425319-B2 | Prevent, maintenance of Dna damage; administering compound which forms nicotinamide-adenine dinucleotide | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) | 2008-09-16 | — | — | US | disclosed |
| EP-1922313-A1 | PYRAZINE DERIVATIVES USEFUL AS ADENOSINE RECEPTOR ANTAGONISTS | Laboratorios Almirall, S.A. (ES) | 2008-05-21 | — | — | EP | disclosed |
| WO-2007017096-A1 | PYRAZINE DERIVATIVES USEFUL AS ADENOSINE RECEPTOR ANTAGONISTS | LABORATORIOS ALMIRALL, S.A. (ES) | 2007-02-15 | — | — | WO | disclosed |
| EP-1272183-B1 | METHODS AND COMPOSITIONS USEFUL IN ENHANCING OXYGEN DELIVERY TO CELLS | NIADYNE CORP (US) | 2006-08-30 | — | — | EP | disclosed |
| US-6924299-B2 | Methods and compositions useful in enhancing oxygen delivery to cells | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) | 2005-08-02 | — | — | US | disclosed |
| US-20050040367-A1 | A liquid stabilizer of an organic onium perchlorate and an organic solvent for the stabilization of halogen-containing polymers to improve the starting color; reduction of cloudiness in highly transparent end products, e.g., hard or soft Polyvinyl Chloride | BAERLOCHER GMBH | 2005-02-24 | — | — | US | disclosed |
| EP-1483442-A2 | NOVEL CATALYTIC ACTIVITIES OF OXIDOREDUCTASES FOR OXIDATION AND/OR BLEACHING | Call, Krimhild (DE) | 2004-12-08 | — | — | EP | disclosed |
| EP-1453905-A2 | STABILIZER COMPOSITION, PRODUCTION AND USE THEREOF | Baerlocher GmbH (DE) | 2004-09-08 | — | — | EP | disclosed |
| US-20040147491-A1 | Prevent, maintenance of Dna damage; administering compound which forms nicotinamide-adenine dinucleotide | NIADYNE, INC. | 2004-07-29 | — | — | US | disclosed |
| EP-1436371-A2 | ENZYMATIC SYSTEMS FOR GENERATING ACTIVE OXYGEN SPECIES FOR REACTING WITH OTHER PRECURSORS TO OBTAIN OXIDATION AND/OR BLEACHING | Call, Krimhild (DE) | 2004-07-14 | — | — | EP | disclosed |
| EP-1412515-A2 | TREATMENT OF CNS DISORDERS USING D-AMINO ACID OXIDASE AND D-ASPARTATE OXIDASE ANTAGONISTS | Genset (FR) | 2004-04-28 | — | — | EP | disclosed |
| WO-2003061550-A2 | NOVEL CATALYTIC ACTIVITIES OF OXIDOREDUCTASES FOR OXIDATION AND/OR BLEACHING | CALL, KRIMHILD (DE) | 2003-07-31 | — | — | WO | disclosed |
| WO-2003054072-A2 | STABILIZER COMPOSITION, PRODUCTION AND USE THEREOF | BAERLOCHER GMBH (DE) | 2003-07-03 | — | — | WO | disclosed |
| US-6552050-B2 | Adjustment of cellular nicotinamide-adenine dinucleotide | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION | 2003-04-22 | — | — | US | disclosed |
| EP-1268430-A1 | CHEMICAL COMPLEX COMPPRISING A PYRIDINE CARBOXY DERIVATIVE AND AN H2 HISTAMINE RECEPTOR ANTAGONIST | Astion Development APS (DK) | 2003-01-02 | — | — | EP | disclosed |
| WO-2002099023-A2 | ENZYMATIC SYSTEMS FOR GENERATING ACTIVE OXYGEN SPECIES FOR REACTING WITH OTHER PRECURSORS TO OBTAIN OXIDATION AND/OR BLEACHING | CALL, KRIMHILD (DE) | 2002-12-12 | — | — | WO | disclosed |
| US-20020123517-A1 | Reducing cell necrosis or apoptosis by administering a pro-NAD compound such as nicotinic acid or nicotinamide; nicotinamide adenine dinucleotide (NAD); manipulating poly(ADP-ribose) polymerase pathways | JACOBSON ELAINE L (US) | 2002-09-05 | — | — | US | disclosed |
| WO-2002066672-A2 | TREATMENT OF CNS DISORDERS USING D-AMINO ACID OXIDASE AND D-ASPARTATE OXIDASE ANTAGONISTS | GENSET S.A. (FR) | 2002-08-29 | — | — | WO | disclosed |
| US-6403619-B1 | TOPICALLY ADMINISTERING PRO-NAD COMPOUND (ESTERS OF NICOTINIC ACID) | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION | 2002-06-11 | — | — | US | disclosed |
| US-6337065-B1 | FOR THERAPY OF DISORDERS SUCH AS SUNBURN AND OTHER SKIN DETERIORATION THAT RESULTS FROM DNA DAMAGE IN SKIN CELLS | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION | 2002-01-08 | — | — | US | disclosed |
| US-20010033848-A1 | Adjustment of cellular nicotinamide-adenine dinucleotide | NIADYNE, INC. | 2001-10-25 | — | — | US | disclosed |
| EP-1143954-A2 | USE OF NICOTONIC ACID DERIVATIVES FOR THE TREATMENT OF DNA DAMAGE IN SKIN CELLS | University of Kentucky Research Foundation (US) | 2001-10-17 | — | — | EP | disclosed |
| WO-2001074780-A1 | CHEMICAL COMPLEX COMPRISING A PYRIDINE CARBOXY DERIVATIVE AND AN H2 HISTAMINE RECEPTOR ANTAGONIST | ASTION DEVELOPMENT APS (DK) | 2001-10-11 | — | — | WO | disclosed |
| EP-1012376-A2 | OXIDATION AND BLEACHING SYSTEM WITH ENZYMATICALLY PRODUCED OXIDIZING AGENTS | Blume, Hildegard (DE) | 2000-06-28 | — | — | EP | disclosed |
| WO-2000032179-A2 | USE OF NICOTONIC ACID DERIVATIVES FOR THE TREATMENT OF DNA DAMAGE IN SKIN CELLS | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) | 2000-06-08 | — | — | WO | disclosed |
| WO-1998059108-A2 | OXIDATION AND BLEACHING SYSTEM WITH ENZYMATICALLY PRODUCED OXIDIZING AGENTS | BLUME, HILDEGARD (DE) | 1998-12-30 | — | — | WO | disclosed |
| EP-0805681-A4 | TOCOLYTIC OXYTOCIN RECEPTOR ANTAGONISTS | MERCK & CO INC (US) | 1998-05-06 | — | — | EP | disclosed |
| EP-0805681-A1 | TOCOLYTIC OXYTOCIN RECEPTOR ANTAGONISTS | Merck & Co., Inc. (US) | 1997-11-12 | — | — | EP | disclosed |
| WO-1996022775-A1 | TOCOLYTIC OXYTOCIN RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 1996-08-01 | — | — | WO | disclosed |
| US-5530134-A | Synthesis of anabaseine, salts and derivatives thereof | SYNPHAR LABORATORIES INC. (CA) | 1996-06-25 | — | — | US | disclosed |
| US-5461155-A | Useful in dye diffusion transfer processes | MINNESOTA MINING AND MANUFACTURING COMPANY (US) | 1995-10-24 | — | — | US | disclosed |
| EP-0508573-B1 | Transfer imaging using metal-azo and metal-azomethine dyes | MINNESOTA MINING & MFG (US) | 1995-06-07 | — | — | EP | disclosed |
| US-5314998-A | Dye-donor sheets for thermal printing | MINNESOTA MINING AND MANUFACTURING COMPANY (US) | 1994-05-24 | — | — | US | disclosed |
| EP-0591016-A1 | Organic solvent-soluble metal-azo and metal-azomethine dyes | MINNESOTA MINING AND MANUFACTURING COMPANY (US) | 1994-04-06 | — | — | EP | disclosed |
| US-5259992-A | Cuprous iodide-pyridine derivative complex | REXHAM GRAPHICS INC. (US) | 1993-11-09 | — | — | US | disclosed |
| US-5180705-A | Monoazo or methine metallized dyes | MINNESOTA MINING AND MANUFACTURING COMPANY (US) | 1993-01-19 | — | — | US | disclosed |
| EP-0508573-A1 | Transfer imaging using metal-azo and metal-azomethine dyes | MINNESOTA MINING AND MANUFACTURING COMPANY (US) | 1992-10-14 | — | — | EP | disclosed |
| US-5098462-A | Herbicides | SANDOZ LTD. (CH) | 1992-03-24 | — | — | US | disclosed |
| US-5098466-A | Herbicides | SANDOZ LTD. (CH) | 1992-03-24 | — | — | US | disclosed |
| US-4511566-A | ANALGESICS | PIERRE FABRE S.A. (FR) | 1985-04-16 | — | — | US | disclosed |
| US-4511566-A | ANALGESICS | PIERRE FABRE S.A. (FR) | 1985-04-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (50 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240050459-A1 | Nicotinyl Riboside Compounds and Their Uses | NADK, NNT, NAMPT | KDM4E 3520/4885TDP1 483/4885ALDH1A1 1563/4885 |
| US-20220062314-A1 | NICOTINYL RIBOSIDE COMPOUNDS AND THEIR USES | NADK, NNT, NAMPT | KDM4E 3520/4885TDP1 483/4885ALDH1A1 1563/4885 |
| US-11286274-B2 | Nicotinamide riboside derivatives and their uses | NME4, NADK, NQO1 | KDM4E 3963/4885TDP1 934/4885ALDH1A1 1331/4885 |
| US-20240261299-A1 | SOLID DOSAGE FORMULATIONS OF AN OREXIN RECEPTOR ANTAGONIST | HCRTR2, HCRTR1, SCTR | KDM4E 745/4885TDP1 4790/4885ALDH1A1 4516/4885 |
| US-20210188810-A1 | HETEROARYL INHIBITORS OF PAD4 | PADI4, PADI1, PADI6 | KDM4E 117/4885TDP1 22/4885ALDH1A1 956/4885 |
| US-12144812-B2 | Formulations of pyrimidine cyclohexyl glucocorticoid receptor modulators | NR3C1, NR3C2, MC2R | KDM4E 1773/4885TDP1 2504/4885ALDH1A1 3410/4885 |
| US-20200347045-A1 | CRBN LIGANDS AND USES THEREOF | CRBN, CRKL, ERBB3 | KDM4E 2459/4885TDP1 3254/4885ALDH1A1 4145/4885 |
| US-20250090465-A1 | Formulations of Enzalutamide | AR, KLK3, NR5A1 | KDM4E 705/4885TDP1 244/4885ALDH1A1 1743/4885 |
| US-20110118351-A1 | Stabilized Formulations of Fatty Acids | FABP4, FABP2, FABP1 | KDM4E 292/4885TDP1 2614/4885ALDH1A1 1223/4885 |
| US-11839689-B2 | Formulations of enzalutamide | AR, KLK3, NR5A1 | KDM4E 705/4885TDP1 244/4885ALDH1A1 1743/4885 |
| US-11980623-B2 | Solid dosage formulations of an orexin receptor antagonist | HCRTR2, HCRTR1, SCTR | KDM4E 745/4885TDP1 4790/4885ALDH1A1 4516/4885 |
| US-20250049721-A1 | Formulations of Enzalutamide | AR, KLK3, NR5A1 | KDM4E 705/4885TDP1 244/4885ALDH1A1 1743/4885 |
| US-11897866-B2 | Heteroaryl inhibitors of PAD4 | PADI4, PADI1, PADI6 | KDM4E 117/4885TDP1 22/4885ALDH1A1 956/4885 |
| US-12599610-B2 | Solid dosage formulations of an orexin receptor antagonist | CRH, HCRTR2, HCRTR1 | KDM4E 130/4885TDP1 3584/4885ALDH1A1 3659/4885 |
| US-20220249388-A1 | NANOPARTICLES COMPRISING ENZALUTAMIDE | AR, KLK3, KLK5 | KDM4E 950/4885TDP1 1752/4885ALDH1A1 836/4885 |
| US-20240024249-A1 | ORAL DOSAGE FORMS HAVING A HIGH LOADING OF A METHYL HYDROGEN FUMARATE PRODRUG | FH, MGMT, CYP4F2 | KDM4E 1434/4885TDP1 2155/4885ALDH1A1 1240/4885 |
| US-11266614-B2 | Oral formulations of belinostat | HDAC11, HDAC3, EZH2 | KDM4E 75/4885TDP1 1229/4885ALDH1A1 2805/4885 |
| US-20220241208-A1 | PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF HBV | HAVCR2, APOB, GYS2 | KDM4E 3363/4885TDP1 2569/4885ALDH1A1 4550/4885 |
| US-20200397807-A1 | NICOTINYL RIBOSIDE COMPOUNDS AND THEIR USES | NADK, NNT, NAMPT | KDM4E 3059/4885TDP1 597/4885ALDH1A1 1331/4885 |
| US-20180362570-A1 | NICOTINAMIDE RIBOSIDE DERIVATIVES AND THEIR USES | NME4, NADK, NQO1 | KDM4E 3963/4885TDP1 934/4885ALDH1A1 1331/4885 |
| US-20090042891-A1 | Pyrazine Derivatives Useful as Adenosine Receptor Antagonists | ADORA2B, ADORA2A, ADORA3 | KDM4E 4367/4885TDP1 3031/4885ALDH1A1 734/4885 |
| US-20240197661-A1 | ORAL DOSAGE FORMS OF METHYL HYDROGEN FUMARATE AND PRODRUGS THEREOF | MGMT, MTHFD2, PHF2 | KDM4E 479/4885TDP1 3572/4885ALDH1A1 2175/4885 |
| US-20230255995-A1 | Nicotinyl Riboside Compounds and Their Uses | NADK, NNT, NAMPT | KDM4E 3059/4885TDP1 597/4885ALDH1A1 1331/4885 |
| US-20220081418-A1 | HETEROARYL INHIBITORS OF PAD4 | PADI4, PADI1, PADI6 | KDM4E 117/4885TDP1 22/4885ALDH1A1 956/4885 |
| US-20020123517-A1 | Reducing cell necrosis or apoptosis by administering a pro-NAD compound such as nicotinic acid or nicotinamide; nicotinamide adenine dinucleotide (NAD); manipulating poly(ADP-ribose) polymerase pathways | NAMPT, NADK, NAPRT | KDM4E 4332/4885TDP1 654/4885ALDH1A1 2067/4885 |
| US-20120308588-A1 | NEPRILYSIN INHIBITORS | MME, REN, ACE | KDM4E 2357/4885TDP1 1269/4885ALDH1A1 2714/4885 |
| US-20230122911-A1 | FORMULATIONS OF ENZALUTAMIDE | AR, KLK3, NR5A1 | KDM4E 705/4885TDP1 244/4885ALDH1A1 1743/4885 |
| US-20120087978-A1 | DOSAGE FORMS OF APIXABAN | PCSK9, VKORC1, PLAT | KDM4E 2861/4885TDP1 2512/4885ALDH1A1 3505/4885 |
| US-20100273757-A1 | PYRAZINE DERIVATIVES USEFUL AS ADENOSINE RECEPTOR ANTAGONISTS | ADORA2B, ADORA2A, ADORA1 | KDM4E 3671/4885TDP1 4435/4885ALDH1A1 742/4885 |
| US-20220062295-A1 | SOLID DOSAGE FORMULATIONS OF AN OREXIN RECEPTOR ANTAGONIST | HCRTR2, HCRTR1, SCTR | KDM4E 745/4885TDP1 4790/4885ALDH1A1 4516/4885 |
| US-20240207264-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING INHIBITORS OF THE ANDROGEN RECEPTOR AND USES THEREOF | AR, NR5A1, SHBG | KDM4E 650/4885TDP1 2606/4885ALDH1A1 2010/4885 |
| US-20220105093-A1 | PHARMACEUTICAL COMPOSITIONS AND COMBINATIONS COMPRISING INHIBITORS OF THE ANDROGEN RECEPTOR AND USES THEREOF | AR, SHBG, NR3C2 | KDM4E 518/4885TDP1 2724/4885ALDH1A1 2655/4885 |
| US-20230210778-A1 | Formulations of Enzalutamide | AR, KLK3, NR5A1 | KDM4E 705/4885TDP1 244/4885ALDH1A1 1743/4885 |
| US-12502357-B2 | Formulations of enzalutamide | AR, KLK3, NR5A1 | KDM4E 705/4885TDP1 244/4885ALDH1A1 1743/4885 |
| US-20250144098-A1 | FORMULATIONS OF PYRIMIDINE CYCLOHEXYL GLUCOCORTICOID RECEPTOR MODULATORS | NR3C1, NR3C2, MC2R | KDM4E 1773/4885TDP1 2504/4885ALDH1A1 3410/4885 |
| US-20040147491-A1 | Prevent, maintenance of Dna damage; administering compound which forms nicotinamide-adenine dinucleotide | NQO1, NNT, NAMPT | KDM4E 3637/4885TDP1 222/4885ALDH1A1 777/4885 |
| US-20250215002-A1 | SOLID FORMS OF TYK2 INHIBITORS AND METHODS OF USE | TYK2, JAK2, SGK2 | KDM4E 478/4885TDP1 350/4885ALDH1A1 4861/4885 |
| US-20250221997-A1 | TYK2 INHIBITOR FORMULATIONS AND METHODS OF MAKING THE SAME | TYK2, JAK1, JAK2 | KDM4E 478/4885TDP1 436/4885ALDH1A1 4873/4885 |
| US-20010033848-A1 | Adjustment of cellular nicotinamide-adenine dinucleotide | NQO1, NNT, NAMPT | KDM4E 3589/4885TDP1 256/4885ALDH1A1 805/4885 |
| US-11833167-B2 | Nicotinyl riboside compounds and their uses | NADK, NNT, NAMPT | KDM4E 3520/4885TDP1 483/4885ALDH1A1 1563/4885 |
| US-12064516-B2 | Pharmaceutical formulations and uses thereof | IL5, CFTR, NQO2 | KDM4E 3856/4885TDP1 3878/4885ALDH1A1 2354/4885 |
| US-12178827-B2 | Nicotinyl riboside compounds and their uses | NADK, NNT, NAMPT | KDM4E 3520/4885TDP1 483/4885ALDH1A1 1563/4885 |
| US-20220340577-A1 | GCN2 INHIBITORS AND USES THEREOF | EIF2AK4, GCN1, GCGR | KDM4E 3944/4885TDP1 2231/4885ALDH1A1 4414/4885 |
| US-20160107992-A1 | INTERMEDIATES USEFUL FOR THE PREPARATION OF SAXAGLIPTIN | DPP4, GLP1R, DPP8 | KDM4E 3531/4885TDP1 4045/4885ALDH1A1 1515/4885 |
| US-20110111998-A1 | MODIFICATION OF PARTICULATE-STABILISED FLUID-FLUID INTERFACES | CD68, EPCAM, TP53 | KDM4E 323/4885TDP1 896/4885ALDH1A1 2505/4885 |
| US-20240261282-A1 | PHARMACEUTICAL COMPOSITIONS AND COMBINATIONS COMPRISING INHIBITORS OF THE ANDROGEN RECEPTOR AND USES THEREOF | AR, NR5A1, SHBG | KDM4E 611/4885TDP1 2904/4885ALDH1A1 2291/4885 |
| US-20250228840-A1 | METHODS OF TREATING SJÖGREN-LARSSEN SYNDROME | SSB, HRH2, ASAH2 | KDM4E 3656/4885TDP1 615/4885ALDH1A1 1676/4885 |
| US-10988477-B2 | GCN2 inhibitors and uses thereof | EIF2AK4, GCN1, EIF2AK1 | KDM4E 2118/4885TDP1 3207/4885ALDH1A1 4754/4885 |
| US-12447128-B2 | Formulations of enzalutamide | AR, KLK3, NR5A1 | KDM4E 705/4885TDP1 244/4885ALDH1A1 1743/4885 |
| US-20250262166-A1 | NANOPARTICLES COMPRISING ENZALUTAMIDE | AR, KLK3, KLK5 | KDM4E 950/4885TDP1 1752/4885ALDH1A1 836/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.